# A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)

> **NCT02964065** · PHASE3 · COMPLETED · sponsor: **Changchun BCHT Biotechnology Co.** · enrollment: 9000 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Live-Attenuated influenza Vaccine(LAIV)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02964065
- **Lead sponsor:** Changchun BCHT Biotechnology Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2017-08
- **Final completion:** —
- **Target enrollment:** 9000 (ACTUAL)
- **Last updated:** 2017-09-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02964065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02964065, "A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02964065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*